Received Mar 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 4 | Z007383 | IM / RA |
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | 5 | Y1D49P1 | SC / RA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | Y017512 | SC / RA |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 4 | F9K3L | IM / LA |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 2 | Z014869 | SC / LA |
MMRV and Varicella were inadvertantly administered at the same time. When identified, Merck was contacted to determine expected adverse effects and need to revaccinate. Per Merck (Service Rep:), adverse effects would be those listed in package inserts with no need to revaccinate. Parent, contacted and reported child experienced no adverse effects and went to school without concern.
None
None
None
None
None